Boston Scientific Receives FDA Approval for Farapulse PFA in Q1
December 29, 2023
☀️Trending News
Boston Scientific ($NYSE:BSX) Corporation is a global medical device company that designs, manufactures and markets a wide range of medical devices to treat cardiovascular, neuromodulation, endoscopy, urology, and other medical conditions. The company’s stock is publicly traded on the New York Stock Exchange under the ticker symbol BSX. In 2021, Boston Scientific anticipates that Farapulse PFA will be approved by the FDA in the first quarter. Farapulse PFA is a medical device that uses radiofrequency energy to treat patients with atrial fibrillation.
The device is also used to treat other cardiac arrhythmias. The approval of Farapulse PFA by the FDA marks a major milestone for Boston Scientific, as it will provide an additional treatment option for patients with atrial fibrillation. Boston Scientific is confident that the FDA’s approval of Farapulse PFA will help to improve the lives of many more patients in the United States.
Price History
Thursday marked a significant milestone for Boston Scientific as the US Food and Drug Administration (FDA) approved the company’s Farapulse PFA, a novel device for the treatment of atrial fibrillation. The news came as a welcome relief to investors as the stock opened at $56.0 and closed at $56.3, representing a 0.5% uptick from its previous closing price of $56.0. This approval marks the first of many new products from Boston Scientific that could potentially create value for its shareholders. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Boston Scientific. More…
| Total Revenues | Net Income | Net Margin |
| 13.76k | 1.19k | 9.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Boston Scientific. More…
| Operations | Investing | Financing |
| 2.35k | -1.7k | -9 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Boston Scientific. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 34.04k | 14.91k | 12.89 |
Key Ratios Snapshot
Some of the financial key ratios for Boston Scientific are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.8% | 35.7% | 15.6% |
| FCF Margin | ROE | ROA |
| 11.7% | 7.2% | 3.9% |
Analysis
At GoodWhale, we conducted an analysis of BOSTON SCIENTIFIC‘s fundamentals. According to our Star Chart, BOSTON SCIENTIFIC is classified as a ‘gorilla’ company, which means that it has achieved stable and high revenue or earnings growth due to its strong competitive advantage. Investors who are interested in investing in such a company should be aware that BOSTON SCIENTIFIC has a high health score of 7/10 when it comes to its cash flows and debt. This indicates that the company has the financial capabilities to pay off debt and fund future operations. Additionally, BOSTON SCIENTIFIC is strong in terms of asset, growth, and profitability, but less so when it comes to dividend payout. More…
Peers
Boston Scientific Corp is one of the leading competitors in the medical device industry. Some of its main competitors are Medtronic PLC, Cyduct Diagnostics Inc, Guided Therapeutics Inc. Boston Scientific Corp has a wide range of products that cater to different markets. This gives the company a competitive advantage over its competitors.
– Medtronic PLC ($NYSE:MDT)
As of 2022, Medtronic PLC has a market cap of 111.05B and a Return on Equity of 7.49%. The company is a medical device company that manufactures and sells a variety of medical devices, including pacemakers, defibrillators, and insulin pumps. Medtronic PLC is headquartered in Dublin, Ireland.
– Cyduct Diagnostics Inc ($OTCPK:CYDX)
Cyduct Diagnostics Inc is a publicly traded company that provides diagnostic testing services. The company’s market cap as of 2022 was 349.68k. The company offers a variety of services including blood tests, urine tests, and other diagnostic tests. Cyduct Diagnostics Inc is headquartered in the United States.
– Guided Therapeutics Inc ($OTCPK:GTHP)
Guided Therapeutics, Inc., a molecular diagnostics company, focuses on the development and commercialization of molecularly targeted photodynamic therapies for the treatment of pre-cancerous lesions and cancer. The company’s products in development include Endocavity Probe, a disposable light emitting diode probe that is inserted into the body cavity for the detection and treatment of diseases; and Esophageal Probe, a light emitting diode probe to be used with the company’s Levulan Kerastick to treat Barrett’s esophagus. It also develops Gynecological Probe, a light emitting diode probe to be used with the company’s Levulan Kerastick to treat cervical intraepithelial neoplasia. The company was formerly known as Light Touch Medical, Inc. and changed its name to Guided Therapeutics, Inc. in November 2009. Guided Therapeutics, Inc. was founded in 1998 and is based in Atlanta, Georgia.
Summary
Boston Scientific (BSX) is an American medical technology company that develops, manufactures, and markets medical devices. The company is well-positioned to benefit from an aging population and an increased demand for medical products, and has seen a steady growth in its share price over the past few years. Recently, the company received FDA approval for Farapulse PFA, its atrial fibrillation therapy.
This is expected to boost its revenue in the first quarter of 2021, making BSX an attractive investment opportunity for investors. The company also has several innovative technologies in development, such as robotic-assisted surgery and minimally invasive treatments for rare diseases, which could further contribute to its growth potential.
Related Posts
Recent Posts
